{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:19:48Z","timestamp":1788023988290,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Obesity is a chronic, relapsing disease associated with multiple serious comorbidities. Semaglutide has emerged as an effective pharmacological option for obesity management, owing to its substantial effects on weight loss, cardiometabolic risk factors, and patient-reported outcomes. This systematic review and meta-analysis evaluated the efficacy and safety of subcutaneous semaglutide for weight management in adults with overweight or obesity without diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized controlled trials comparing subcutaneous semaglutide with placebo in adults with overweight or obesity without diabetes were identified through systematic searches of PubMed, the Cochrane Library, and ClinicalTrials.gov. Outcomes included changes in body weight, waist circumference, C-reactive protein (CRP) and serious adverse events (SAEs). A quality assessment and meta-analysis were performed using REVMAN 10.1.1 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across nine trials including 6 239 participants, subcutaneous semaglutide significantly reduced percentage body weight from baseline (mean difference [MD] \u221212.04%, 95% CI \u221213.08 to \u221211.00), waist circumference (MD \u22129.36\u2009cm, 95% CI \u221210.27 to \u22128.45), and CRP (MD \u221240.90%, 95% CI \u221246.37 to \u221235.42) versus placebo (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). The risk of SAEs did not differ significantly between semaglutide and placebo (risk ratio [RR] 1.12, 95% CI 0.76 to 1.65;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.55).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Subcutaneous semaglutide is effective for weight management in adults with overweight or obesity without diabetes. The recently published STEP UP trial evaluating semaglutide 7.2\u2009mg provides additional evidence on higher-dose regimens and showed greater weight reduction compared with previously available data, representing a meaningful new contribution to the literature. Longer-term studies are needed to better define the long-term efficacy and safety profile of semaglutide across clinical populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-026-02189-x","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:05:57Z","timestamp":1788023157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-5697","authenticated-orcid":false,"given":"Agostino","family":"Milluzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5210-8601","authenticated-orcid":false,"given":"Vittorio","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-5142","authenticated-orcid":false,"given":"Lucia","family":"Manuella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9764-0295","authenticated-orcid":false,"given":"Alfredo","family":"Pulvirenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-5828","authenticated-orcid":false,"given":"Lucia","family":"Frittitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2189_CR1","unstructured":"World Health Organization. Obesity and overweight 2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"2189_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. https:\/\/doi.org\/10.1186\/1471-2458-9-88.","journal-title":"BMC Public Health"},{"key":"2189_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/amp0000517","volume":"75","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75:235\u201351. https:\/\/doi.org\/10.1037\/amp0000517.","journal-title":"Am Psychol"},{"key":"2189_CR4","doi-asserted-by":"publisher","first-page":"f5934","DOI":"10.1136\/bmj.f5934","volume":"347","author":"VL Gloy","year":"2013","unstructured":"Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934. https:\/\/doi.org\/10.1136\/bmj.f5934.","journal-title":"BMJ"},{"key":"2189_CR5","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1111\/dom.15114","volume":"25","author":"R Seetharaman","year":"2023","unstructured":"Seetharaman R. Inclusion of drugs on the World Health Organization\u2019s Essential Medicines List: a game-changer for obesity? Diab Obes Metab. 2023;25:2423\u20134. https:\/\/doi.org\/10.1111\/dom.15114.","journal-title":"Diab Obes Metab"},{"key":"2189_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2146\/ajhp150990","volume":"73","author":"D Isaacs","year":"2016","unstructured":"Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am J Health Syst Pharm. 2016;73:1493\u2013507. https:\/\/doi.org\/10.2146\/ajhp150990.","journal-title":"Am J Health Syst Pharm"},{"key":"2189_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obes (Silver Spring). 2020;28:1050\u201361. https:\/\/doi.org\/10.1002\/oby.22794.","journal-title":"Obes (Silver Spring)"},{"key":"2189_CR8","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u201325. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"key":"2189_CR9","doi-asserted-by":"publisher","first-page":"842","DOI":"10.46747\/cfp.6711842","volume":"67","author":"M Ojeniran","year":"2021","unstructured":"Ojeniran M, Dube B, Paige A, Ton J, Lindblad AJ. Semaglutide for weight loss. Can Fam Physician. 2021;67:842. https:\/\/doi.org\/10.46747\/cfp.6711842.","journal-title":"Can Fam Physician"},{"key":"2189_CR10","doi-asserted-by":"publisher","unstructured":"Alabduljabbar K, Al-Najim W, le Roux CW. The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials. Nutrients. 2022;14. https:\/\/doi.org\/10.3390\/nu14112217.","DOI":"10.3390\/nu14112217"},{"key":"2189_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmesaeth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diab Endocrinol. 2025;13:949\u201363. https:\/\/doi.org\/10.1016\/S2213-8587(25)00226-8.","journal-title":"Lancet Diab Endocrinol"},{"key":"2189_CR12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"2189_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diab Care. 2025;48:292\u2013300. https:\/\/doi.org\/10.2337\/dc24-1678.","journal-title":"Diab Care"},{"key":"2189_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","volume":"30","author":"HUH Ansari","year":"2024","unstructured":"Ansari HUH, Qazi SU, Sajid F, Altaf Z, Ghazanfar S, Naveed N, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pr. 2024;30:160\u201371. https:\/\/doi.org\/10.1016\/j.eprac.2023.11.007.","journal-title":"Endocr Pr"},{"key":"2189_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietilainen KH, Muniraju HAK, et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diab Endocrinol. 2024;12:631\u201342. https:\/\/doi.org\/10.1016\/S2213-8587(24)00182-7.","journal-title":"Lancet Diab Endocrinol"},{"key":"2189_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"key":"2189_CR17","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583.","journal-title":"PLoS Med"},{"key":"2189_CR18","unstructured":"Higgins JPT CJ, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions Version 6.4 (updated August 2023): Cochrane.2023 Available from training.cochrane.org\/handbook."},{"key":"2189_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2189_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"2189_CR21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"key":"2189_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"key":"2189_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, Sorrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"2189_CR24","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391:1573\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2403664.","journal-title":"N Engl J Med"},{"key":"2189_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","volume":"37","author":"HC Tan","year":"2022","unstructured":"Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37:65\u201372. https:\/\/doi.org\/10.15605\/jafes.037.02.14.","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"2189_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/dom.15386","volume":"26","author":"W Qin","year":"2024","unstructured":"Qin W, Yang J, Deng C, Ruan Q, Duan K. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial. Diab Obes Metab. 2024;26:911\u201323. https:\/\/doi.org\/10.1111\/dom.15386.","journal-title":"Diab Obes Metab"},{"key":"2189_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015092.pub2","volume":"10","author":"J Bracchiglione","year":"2025","unstructured":"Bracchiglione J, Meza N, Franco JV, Escobar Liquitay CM, Novik AV, Ocara Vargas M, et al. Semaglutide for adults living with obesity. Cochrane Database Syst Rev. 2025;10:CD015092. https:\/\/doi.org\/10.1002\/14651858.CD015092.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2189_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02189-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02189-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02189-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:05:58Z","timestamp":1788023158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02189-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":28,"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02189-x","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM was the recipient of a research fellowship funded by Novo Nordisk at the University of Catania during 2023\u20132024 and received a one-time honorarium from Novo Nordisk in 2023 for participation as faculty in a one-day educational course. LF has acted as a consultant and speaker for Lilly and Novo-Nordisk and has received a grant from Novo Nordisk. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Ethics approval and informed consent were not required for this study because it is a systematic review and meta-analysis based exclusively on previously published studies.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}